Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 240

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 240
---
, the Company borrowed $ 0.2million from Prophase (the “Prophase March 2025 Loan”). The Prophase March 2025 Loan bears interest at 6% per annum and is due on June 6, 2025, which may be extended upon mutual agreement of the parties. As of March 31, 2025 and December 31, 2024, the balance of the Prophase loans is $ 2.0million and $ 1.6million, respectively. As of March 31, 2025 and December 31, 2024, the related accrued interest of the loans from Prophase was $ 0.1million, respectively, and is included in accrued interest, related parties in the unaudited condensed balance sheets. For the three months ended March 31, 2025 and 2024, interest expense related to the Prophase Loans was less than $ 0.1million, respectively. See Note 5 for discussion related to notes which have passed their maturity dates. Hana Loans On August 1, 2024, the Company borrowed $ 0.9million from Hana Immunotherapeutics, LLC (“Hana”), a related party of the Company due to having common executives (the “Hana Loans”). The Hana Loans bear interest at 6% per annum and were due on September 30, 2024 and October 26, 2024, which may be extended upon mutual agreement of the parties.

<div align='center'>F-31</div>

As of March 31, 2025 and December 31, 2024, the balance of the Hana Loans is $ 0.9million, respectively. As of March 31, 2025 and December 31, 2024, the related accrued interest of the loans from Hana was less than $ 0.1million, respectively, and is included in accrued interest, related parties in the unaudited condensed balance sheets. For the three months ended March 31, 2025 and 2024, interest expense related to the Hana Loans was less than $ 0.1million and $ 0, respectively. See Note 5 for discussion related to notes which have passed their maturity dates. Amantes Loans On November 1, 2024, the Company borrowed $ 0.4million from Amantes LLC (“Amantes”), a related party of the Company due to having common executives, pursuant to